ArticleInternational journal of clinical and experimental pathology2019
Eukaryotic initiation factor 3B downregulation suppresses cell proliferation, migration and invasion while it induces cell apoptosis by blocking the β-catenin pathway in endometrial cancer.
Article in International journal of clinical and experimental pathology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 4 citations in OpenAlex.
- Eukaryotic initiation factor 3b regulates the development and progression of breast cancer.American journal of cancer research · 2023Article
- Eukaryotic translation initiation factor 3 subunit B could serve as a potential prognostic predictor for breast cancer.Bioengineered · 2022Article
- Review
- miR-532-3p Inhibits Proliferation and Promotes Apoptosis of Lymphoma Cells by Targeting β-Catenin.Journal of Cancer · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to evaluate the effect of eukaryotic initiation factor 3B (EIF3B) downregulation on cell proliferation, apoptosis, migration, invasion and the β-catenin pathway in endometrial cancer. EIF3B mRNA and protein expressions were determined in human endometrial cancer cell lines (Ishikawa, HEC-1A, RL95-2 and EFE-184) and in the normal human endometrial epithelial cell line (HEEC). EIF3B siRNA and a control siRNA were transfected into HEC-1A cells, then cell proliferation, apoptosis, apoptotic marker (C-caspase 3 and Bcl-2) expressions, cell migration, and invasion were determined. β-catenin and cyclin E1 (CCNE1) expressions were also measured. EIF3B mRNA and protein expressions were increased in the Ishikawa, HEC-1A and RL95-2 cell lines, but they were similar in the EFE-184 cell line compared to the HEEC cell line. In HEC-1A cells, EIF3B siRNA suppressed cell proliferation, but it elevated the cell apoptosis rate compared to the control siRNA, and EIF3B siRNA also enhanced C-caspase 3 expression, but it inhibited Bcl-2 expression. Also, EIF3B siRNA reduced cell migration and cell invasion compared to the control siRNA in HEC-1A cells. More interestingly, EIF3B siRNA reduced β-catenin and CCNE1 mRNA as well as protein expressions compared with the control siRNA in HEC-1A cells. In conclusion, EIF3B downregulation suppresses cell proliferation, migration, and invasion, but it induces cell apoptosis by blocking the β-catenin pathway in endometrial cancer.
Indexed as
Identifiers
31934209PMC6949831W3027273193What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.